aladdin 阿拉丁 A407844 Abemaciclib mesylate (LY2835219) 1231930-82-7 10mM in DMSO

中文名：Abemaciclib mesylate (LY2835219)

英文名：Abemaciclib mesylate (LY2835219)

英文别名：2-Pyrimidinamine, N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-, methanesulfonate (1:1)

纯度：10mM in DMSO

货号：A407844

包装：1ml

Cas号：1231930-82-7

存储温度：-80℃储存

产品介绍：

Information

Abemaciclib mesylate (LY2835219) Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
In vitro

LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.

In vivo

LY2835219 saturates BBB efflux with an unbound plasma IC50 of about 95 nM. The percent of dose in brain for LY2835219-MsOH is 0.5–3.9%. In both a subcutaneous and intracranial human glioblastoma model (U87MG), LY2835219-MsOH suppressed tumor growth in a dose-dependent manner both as a single agent, and in combination with temozolomide.
Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥98%

查看阿拉丁官网此产品相关对应页面：https://www.aladdin-e.com/zh_cn/A407844.html